p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Current therapy against colorectal cancer (CRC) is based on DNA-damaging agents that remain ineffective in a proportion of patients. Whether and how non-curative DNA damage-based treatment affects tumor cell behavior and patient outcome is primarily unstudied. Using CRC patient-derived organoids (PDO)s, we show that sublethal doses of chemotherapy (CT) does not select previously resistant tumor populations but induces a quiescent state specifically to TP53 wildtype (WT) cancer cells, which is linked to the acquisition of a YAP1-dependent fetal phenotype. Cells displaying this phenotype exhibit high tumor-initiating and metastatic activity. Nuclear YAP1 and fetal traits are present in a proportion of tumors at diagnosis and predict poor prognosis in patients carrying TP53 WT CRC tumors. We provide data indicating the higher efficacy of CT together with YAP1 inhibitors for eradication of therapy resistant TP53 WT cancer cells. Together these results identify fetal conversion as a useful biomarker for patient prognosis and therapy prescription.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 1×
“…TPM2 HUNK KCNK5 SLC27A2 HOOK1 MYB CDX1 AGMAT PDSS1 A D 28up-high/8down-low 28up-low/8down-high 21% 74% 5% 64% 34% 2% Subtype CMS1 CMS4 CMS2 CMS3 NOLBL Guinney et al., 2015 Lee et al., 2020 J tSNE_1 tS N E_ 2 5 0 -5 -10 0 5 10-5 tSNE_1 tS N E_ 2 5 0 -5 -10 0 5 10-5 S100A4 PLAUR tSNE_1 tS N E_…”
Self-citationSenolytics improve physical function and increase lifespan in old age
Xu, M., Pirtskhalava, T., Farr, J. N., Weigand, B. M., Palmer, A. K., Weivoda, M. M., Inman, C. L., Ogrodnik, M. B., Hachfeld, C. M., Fraser, D. G., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0092-9 · Cited by 2,287
Senescence in Health and Disease
He, S., & Sharpless, N. E. (2017) · Cell · doi:10.1016/j.cell.2017.05.015 · Cited by 1,766
Senescence-associated reprogramming promotes cancer stemness
Milanovic, M., Fan, D. N. Y., Belenki, D., Däbritz, J. H. M., Zhao, Z., Yu, Y., Dörr, J. R., Dimitrova, L., Lenze, D., Monteiro Barbosa, I. A., et al. (2018) · Nature · doi:10.1038/nature25167 · Cited by 1,131
Merlos-Suárez, A., Barriga, F. M., Jung, P., Iglesias, M., Céspedes, M. V., Rossell, D., Sevillano, M., Hernando-Momblona, X., da Silva-Diz, V., Muñoz, P., et al. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.02.020 · Cited by 934
Self-citationUnmasking senescence: context-dependent effects of SASP in cancer
Faget, D. V., Ren, Q., & Stewart, S. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0156-2 · Cited by 863
Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance
Liau, B. B., Sievers, C., Donohue, L. K., Gillespie, S. M., Flavahan, W. A., Miller, T. E., Venteicher, A. S., Hebert, C. H., Carey, C. D., Rodig, S. J., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2016.11.003 · Cited by 535
Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy
Rehman, S. K., Haynes, J., Collignon, E., Brown, K. R., Wang, Y., Nixon, A. M. L., Bruce, J. P., Wintersinger, J. A., Singh Mer, A., Lo, E. B. L., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.018 · Cited by 495
Tumor cell escape from therapy-induced senescence as a model of disease recurrence after dormancy.
Saleh, T., Tyutyunyk-Massey, L., & Gewirtz, D. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3437 · Cited by 259
Cited by
Understanding the complexity of p53 in a new era of tumor suppression
Liu, Y., Su, Z., Tavana, O., & Gu, W. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.009 · Cited by 495
Cancer cell plasticity during tumor progression, metastasis and response to therapy
Pérez-González, A., Bévant, K., & Blanpain, C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00595-y · Cited by 332
Loh, J.-J., & Ma, S. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.04.004 · Cited by 314
Metastatic recurrence in colorectal cancer arises from residual EMP1+ cells
Cañellas-Socias, A., Cortina, C., Hernando-Momblona, X., Palomo-Ponce, S., Mulholland, E. J., Turon, G., Mateo, L., Conti, S., Roman, O., Sevillano, M., et al. (2022) · Nature · doi:10.1038/s41586-022-05402-9 · Cited by 256
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities
Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E., Sogari, A., Toh, T. S., Balaban, N. Q., Batlle, E., et al. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00737-z · Cited by 210
Metadata
- Authors
- Solé, L., Lobo-Jarne, T., Álvarez-Villanueva, D., Alonso-Marañón, J., Guillén, Y., Guix, M., Sangrador, I., Rozalén, C., Vert, A., Barbachano, A., Lop, J., Salido, M., Bellosillo, B., García-Romero, R., Garrido, M., González, J., Martínez-Iniesta, M., López-Arribillaga, E., Salazar, R., Montagut, C., Torres, F., Iglesias, M., Celià-Terrassa, T., Muñoz, A., Villanueva, A., Bigas, A., & Espinosa, L.
- Venue
- Nature Communications
- Published
- 2022-05-23
- Volume
- 13
- Issue
- 1
- Pages
- 2866-2866
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W4281396271
- Cited by
- 60
- References
- 10
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis. https://app.cochat.ai/papers/10.1038/s41467-022-30382-9
- The paper
- Solé, L., Lobo-Jarne, T., Álvarez-Villanueva, D., Alonso-Marañón, J., Guillén, Y., Guix, M., Sangrador, I., Rozalén, C., Vert, A., Barbachano, A., Lop, J., Salido, M., Bellosillo, B., García-Romero, R., Garrido, M., González, J., Martínez-Iniesta, M., López-Arribillaga, E., Salazar, R., . . . Espinosa, L. (2022). p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis. Nature Communications. https://doi.org/10.1038/s41467-022-30382-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.